Mature pharmaceutical products, including legacy brands as well as generics and biosimilars, play a central role in healthcare systems and company portfolios. For established pharma companies, mature brands remain a critical source of revenue and cash flow, but face increasing pressure from generic and biosimilar competition, evolving treatment guidelines, and shifting payer expectations. At the same time, generics and biosimilars are essential to ensuring access to affordable medicines and supporting healthcare system sustainability, yet operate in highly competitive environments characterized by significant margin pressure and complex regulatory and pricing dynamics.

Maximizing the value of mature portfolios requires disciplined lifecycle management and strategic portfolio allocation. This includes line extensions, label expansions, targeted geographic rollouts, and brand repositioning for originator products, alongside optimized launch timing, manufacturing scale, and supply chain reliability for generics and biosimilars. Biosimilars in particular require strong clinical evidence and stakeholder engagement to build trust with prescribers, payers, and patients, while navigating heterogeneous regulatory requirements across markets.

Global considerations play a critical role in shaping strategy, as geopolitical factors such as trade policies, tariffs, and pricing regulations influence market access, cross-border expansion, and pricing strategies. Companies must make rigorous decisions regarding investment, divestment, partnerships, and resource allocation, leveraging mature franchises not only to sustain performance but also to fund innovation in specialty care, support M&A activities, and enable broader strategic initiatives, including digital patient engagement.

We help generics and biosimilar companies navigate these challenges across the full range of strategic and operational dimensions. 

  • Corporate Strategy: we support portfolio optimization and asset prioritization across originators, generics, and biosimilars, define 3- to 5-year growth and expansion plans, assess global market opportunities, and design business models that balance legacy revenue streams with investments in innovation, while accounting for market-specific pricing pressures
  • Customer Insights: we map key stakeholders – including prescribers, payers, pharmacists, and patients – capture the voice of customers, identify underserved segments, and refine value propositions to optimize adoption, access, and engagement across mature and off-patent portfolios
  • Commercial Strategy: we develop go-to-market models, launch readiness plans (including lifecycle extensions and biosimilar entry), commercial excellence programs, competitive benchmarking, pricing strategies, and differentiation approaches to maximize market share in highly competitive environments
  • Market Access: we design access strategies, optimize pricing and reimbursement frameworks, and support public affairs and value-based healthcare initiatives to navigate payer complexity and sustain coverage and revenue across geographies
  • R&D and Lifecycle Management: we advise on lifecycle management strategies (e.g., line extensions, label optimization), portfolio prioritization, and process efficiency to ensure mature products and biosimilars continue to deliver value over time
  • M&A and Transactions: we deliver commercial and vendor due diligence, build-up strategies, value creation plans, and post-merger integration support

By combining sector expertise with end-to-end advisory support, we help generics and biosimilar companies capture growth, mitigate geopolitical and regulatory risks, optimize portfolios, improve operational efficiency, and deliver sustainable value for patients, payers, and shareholders.